{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:41:20Z","timestamp":1787071280491,"version":"build-2736575974"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Locally advanced pancreatic cancer (LAPC) is currently treated with chemotherapy (CT) alone or CT combined with radiation therapy (RT) (CT+RT). There is no robust evidence supporting one over the other. The present study compares the two treatment modalities in terms of their survival outcomes and safety profile.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>The retrospective study includes 29 nonmetastatic, unresectable, LAPC patients who were treated with CT+RT (21 patients) or CT alone (8 patients) during November 2019 to September 2023. CT consisted of FOLFIRINOX or Gemcitabine-based regimens. CT+RT patients were treated with conventional (50.4 Gy\/28fr) as well as hypofractionated RT dose schedules (39 Gy\/13fr, 25 Gy\/5fr, and 42 Gy\/6fr). The primary endpoint of the study was the median overall survival (OS), and the secondary endpoints were the median progression-free survival (PFS) and acute and late radiation-induced toxicities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      At a median follow-up of 24 months, patients of CT+RT group had prolonged survival compared to patients of CT alone group with median OS of 20 months versus 7 months (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.0032) and median PFS of 15 months versus 5 months (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.029). The majority of toxicities in CT+RT group were Grade 1\u20132 around 79%. However, Grade 3 or more late event was seen only in 1 (5%) patient.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Incorporating radiation therapy along with CT should be the standard approach for unresectable LAPC patients improving survival with acceptable toxicities.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jcrt.jcrt_1747_24","type":"journal-article","created":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T17:00:10Z","timestamp":1758906010000},"page":"1000-1005","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["The impact of radiation therapy and chemotherapy in locally advanced unresectable nonmetastatic pancreatic cancer patients treated in a tertiary care center"],"prefix":"10.4103","volume":"21","author":[{"given":"Zarmina","family":"Alam","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Mahamana Pandit Madan Mohan Malaviya Cancer Centre and Homi Bhabha Cancer Hospital, Tata Memorial Centre, Homi Bhabha National Institute, Varanasi, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satyajit","family":"Pradhan","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Mahamana Pandit Madan Mohan Malaviya Cancer Centre and Homi Bhabha Cancer Hospital, Tata Memorial Centre, Homi Bhabha National Institute, Varanasi, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Shinghal","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Mahamana Pandit Madan Mohan Malaviya Cancer Centre and Homi Bhabha Cancer Hospital, Tata Memorial Centre, Homi Bhabha National Institute, Varanasi, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lincoln","family":"Pujari","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Mahamana Pandit Madan Mohan Malaviya Cancer Centre and Homi Bhabha Cancer Hospital, Tata Memorial Centre, Homi Bhabha National Institute, Varanasi, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akhil","family":"Kapoor","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Mahamana Pandit Madan Mohan Malaviya Cancer Centre and Homi Bhabha Cancer Hospital, Tata Memorial Centre, Homi Bhabha National Institute, Varanasi, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prashanth","family":"Giridhar","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Mahamana Pandit Madan Mohan Malaviya Cancer Centre and Homi Bhabha Cancer Hospital, Tata Memorial Centre, Homi Bhabha National Institute, Varanasi, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankita Rungta","family":"Kapoor","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Mahamana Pandit Madan Mohan Malaviya Cancer Centre and Homi Bhabha Cancer Hospital, Tata Memorial Centre, Homi Bhabha National Institute, Varanasi, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Tanvee","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Mahamana Pandit Madan Mohan Malaviya Cancer Centre and Homi Bhabha Cancer Hospital, Tata Memorial Centre, Homi Bhabha National Institute, Varanasi, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayank","family":"Tripathi","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Mahamana Pandit Madan Mohan Malaviya Cancer Centre and Homi Bhabha Cancer Hospital, Tata Memorial Centre, Homi Bhabha National Institute, Varanasi, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashutosh","family":"Mukherji","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Mahamana Pandit Madan Mohan Malaviya Cancer Centre and Homi Bhabha Cancer Hospital, Tata Memorial Centre, Homi Bhabha National Institute, Varanasi, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,9,26]]},"reference":[{"key":"R2-20250929","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1002\/1097-0142(19951101)76:9<1671::AID-CNCR2820760926>3.0.CO;2-R","article-title":"The National Cancer Data Base report on pancreatic cancer","volume":"76","author":"Niederhuber","year":"1995","journal-title":"Cancer"},{"key":"R3-20250929","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1053\/j.gastro.2013.11.004","article-title":"Pancreatic Ductal Adenocarcinoma Radiology Reporting Template:Consensus Statement of the Society of Abdominal Radiology and the American Pancreatic Association","volume":"146","author":"Al-Hawary","year":"2014","journal-title":"Gastroenterology"},{"key":"R5-20250929","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.jss.2024.03.035","article-title":"Role of diagnostic laparoscopy during pancreatic cancer surgery in the modern era","volume":"298","author":"Chang","year":"2024","journal-title":"J Surg Res"},{"key":"R6-20250929","doi-asserted-by":"crossref","first-page":"4417","DOI":"10.1245\/s10434-023-13353-2","article-title":"FOLFIRINOX or gemcitabine-based chemotherapy for borderline resectable and locally advanced pancreatic cancer:A multi-institutional, patient-level, meta-analysis and systematic review","volume":"30","author":"Eshmuminov","year":"2023","journal-title":"Ann Surg Oncol"},{"key":"R7-20250929","first-page":"164","article-title":"Multi-drug chemotherapy with and without radiation for carcinoma of the stomach and pancreas:A prospective randomized trial","volume":"32","author":"Hazel","year":"1981","journal-title":"J Can Assoc Radiol"},{"key":"R8-20250929","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1200\/JCO.1985.3.3.373","article-title":"Treatment of locally unresectable cancer of the stomach and pancreas:A randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil--an Eastern Cooperative Oncology Group study","volume":"3","author":"Klaassen","year":"1985","journal-title":"J Clin Oncol"},{"key":"R9-20250929","first-page":"751","article-title":"Gastrointestinal Tumor Study Group","volume":"80","year":"1988","journal-title":"J Natl Cancer Inst"},{"key":"R10-20250929","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1093\/annonc\/mdn281","article-title":"Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000\u201301 FFCD\/SFRO study","volume":"19","author":"Chauffert","year":"2008","journal-title":"Ann Oncol"},{"key":"R11-20250929","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1038\/sj.bjc.6603719","article-title":"Systematic review, including meta-analyses, on the management of locally advanced pancreatic cancer using radiation\/combined modality therapy","volume":"96","author":"Sultana","year":"2007","journal-title":"Br J Cancer"},{"key":"R12-20250929","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1200\/JCO.2008.19.7921","article-title":"Chemoradiotherapy in the management of locally advanced pancreatic carcinoma:A qualitative systematic review","volume":"27","author":"Huguet","year":"2009","journal-title":"J Clin Oncol"},{"key":"R13-20250929","doi-asserted-by":"crossref","first-page":"4105","DOI":"10.1200\/JCO.2011.34.8904","article-title":"Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer:An Eastern Cooperative Oncology Group trial","volume":"29","author":"Loehrer","year":"2011","journal-title":"J Clin Oncol"},{"key":"R14-20250929","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S1470-2045(13)70021-4","article-title":"Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP):A multicentre, randomised, phase 2 trial","volume":"14","author":"Mukherjee","year":"2013","journal-title":"Lancet Oncol"},{"key":"R15-20250929","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1001\/jamaoncol.2019.0892","article-title":"Total neoadjuvant therapy with folfirinox in combination with losartan followed by chemoradiotherapy for locally advanced pancreatic cancer:A Phase 2 clinical trial","volume":"5","author":"Murphy","year":"2019","journal-title":"JAMA Oncol"},{"key":"R16-20250929","first-page":"004","article-title":"Clinical results of radiotherapy for locally advanced stage III pancreatic cancer:A single institutional experience","volume":"1","author":"Yoshiomi","year":"2018","journal-title":"Int J Oncol Res"},{"key":"R17-20250929","doi-asserted-by":"crossref","first-page":"325","DOI":"10.14740\/wjon1604","article-title":"Folfirinox vs. Gemcitabine +Nab-paclitaxel as the first-line treatment for pancreatic cancer:A systematic review and meta-analysis","volume":"14","author":"Merza","year":"2023","journal-title":"World J Oncol"},{"key":"R18-20250929","first-page":"100778","article-title":"Hypofractionated radiotherapy concomitant to capecitabine after induction chemotherapy for advanced pancreatic adenocarcinoma","volume":"47","author":"Passoni","year":"2024","journal-title":"Clin Transl Radiat Oncol"},{"key":"R19-20250929","first-page":"100753","article-title":"Dose-escalated SBRT for borderline and locally advanced pancreatic cancer. Feasibility, safety and preliminary clinical results of a multicenter study","volume":"45","author":"Salas","year":"2024","journal-title":"Clin Transl Radiat Oncol"},{"key":"R20-20250929","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.ijrobp.2009.08.046","article-title":"Stereotactic body radiotherapy and gemcitabine for locally advanced pancreatic cancer","volume":"78","author":"Mahadevan","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R21-20250929","doi-asserted-by":"crossref","first-page":"3771","DOI":"10.3390\/cancers15153771","article-title":"Normo- or hypo-fractionated photon or proton radiotherapy in the management of locally advanced unresectable pancreatic cancer:A systematic review","volume":"15","author":"Elkhamisy","year":"2023","journal-title":"Cancers (Basel)"},{"key":"R22-20250929","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.3390\/cancers15082213","article-title":"Survival outcomes and failure patterns in patients with inoperable non-metastatic pancreatic cancer treated with definitive radiotherapy","volume":"15","author":"Cao","year":"2023","journal-title":"Cancers (Basel)"},{"key":"R23-20250929","doi-asserted-by":"crossref","first-page":"101471","DOI":"10.1016\/j.adro.2024.101471","article-title":"Patterns of failure in patients with borderline resectable\/locally advanced pancreatic cancer after preoperative chemotherapy and stereotactic body radiation therapy","volume":"9","author":"Chung","year":"2024","journal-title":"Adv Radiat Oncol"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_1747_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:44:04Z","timestamp":1787067844000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_1747_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_1747_24","relation":{},"ISSN":["0973-1482","1998-4138"],"issn-type":[{"value":"0973-1482","type":"print"},{"value":"1998-4138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"2024-09-09","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-21","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}